Hydroxyurea suppresses HCV replication in humans: A Phase I trial of oral hydroxyurea in chronic hepatitis C patients

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1179-1183

  Nozaki, Akito ^a   Numata, Kazushi ^a   Morimoto, Manabu ^a   Kondo, Masaaki ^a   Sugimori, Kazuya ^a   Morita, Satoshi ^a   Miyajima, Eiji ^a   Ikeda, Masanori ^b   Kato, Nobuyuki ^b   Maeda, Shin ^c   Tanaka, Katsuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MALE; NAIL COLOR DEFECT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS REPLICATION;

ADMINISTRATION, ORAL; AGED; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYDROXYUREA; JAPAN; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; RNA, VIRAL; VIRUS REPLICATION;

EID: 78650991081     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1668     Document Type: Article

References (23)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
2. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-364.
3. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87:6547-6549.
4. Thomas DL. Hepatitis C epidemiology. Curr Top Microbiol Immunol 2000; 242:25-41.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
7. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 2005; 329:1350-1359.
8. Naka K, Ikeda M, Abe K, Dansako H, Kato N. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-α. Biochem Biophys Res Commun 2005; 330:871-879.
9. Nozaki A, Morimoto M, Kondo M, et al. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Arch Virol 2010; 155:601-605.
10. Zala C, Rouleau D, Montaner JS. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection. Clin Infect Dis 2000; 30 Suppl 2:S143-S150. (Pubitemid 32268982)
11. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805.
12. Sergerie Y, Boivin G. Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes. Antiviral Res 2008; 77:77-80.
13. Lori F, Jessen H, Lieberman J, et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999; 180:1827-1832.
14. Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 1980; 46:455-462.
15. Bachir D, Hulin A, Huet E, et al. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Hemoglobin 2007; 31:417-425.
16. Berry DA. Monitoring accumulating data in a clinical trial. Biometrics 1989; 45:1197-1211.
17. Berry DA. A case for Bayesianism in clinical trials. Stat Med 1993; 12:1377-1393.
18. Saban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 2009; 64:213-221.
19. Foli A, Maiocchi MA, Lisziewicz J, Lori F. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis 2007; 196:1409-1415.
20. + T lymphocytes. J Gen Virol 2008; 89:984-993.
21. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19:111-122.
22. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16:649-654.
23. Reichard O, Yun ZB, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41:99-102.